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The use of modular endoprostheses is a viable option to manage both tumor resection and severe bone loss due to nonneoplastic
conditions such as fracture sequelae, failed osteoarticular grafts, arthroplasty revisions, and periprosthetic fractures. We sought to
investigate both midterm complications and failures occurred in 87 patients who underwent a megaprosthetic reconstruction in a
nonneoplastic setting. After a mean follow-up of 58 (1–167) months, overall failure-free survival was 91.5% at 1 year, 80% at 2 years,
71.6% at 5 years, and 69.1% at 5 and 10 years. There was no significant difference in the survival rate according to the diagnosis
at the index procedure (𝑝 = 0.921), nor to the reconstruction site (𝑝 = 0.402). The use of megaprostheses in a postneoplastic
setting did not affect survival rate in comparison with endoprosthetic reconstruction of pure nonneoplastic conditions (𝑝 = 0.851).
Perimegaprosthetic infection was the leading complication, occurring in 10 (11.5%) patients and implying amegaprosthetic revision
in all but one case. Physicians should consider these results when discussing with patients desired outcomes of endoprosthetic
reconstructions of a nonneoplastic disease.
1. Introduction
Modular endoprosthesis is a well-established reconstructive
device in orthopaedic oncology to manage wide bone resec-
tions due to the relatively simple and quick intraoperative
assembly and immediate mechanical stability, allowing early
weight bearing and functional recovery [1]. The outstanding
advances in both megaprostheses’ materials and designs
allowed progressively expanding the indications for their use
in the treatment of nonneoplastic conditions, as in the case
of acute trauma in severe bone loss and poor bone quality,
posttraumatic failures represented by complex nonunions
and critical size bone defects, major bone loss in prosthetic
revision, periprosthetic fractures with component loosening,
and poor bone stock [2–14].
Two recent systematic reviews [6, 7] focused on the
widespread use ofmodular endoprostheses for nonneoplastic
conditions. Authors found an overall midterm survival rate
of 76% for proximal femoral prostheses [6] and 83% for distal
femoral prostheses [7]. Notably, posttraumatic, infective, and
periprosthetic conditions have peculiar characteristics that
are very different to those of oncologic patients. Patient’s
general condition and comorbidities, soft-tissue status, lesion
characteristics, muscle depletion, previous surgeries, pres-
ence of adhesions, and any previous sepsis all are factors
that must be carefully considered when usingmegaprosthesis
in such cases [5]. In this light, to maximize functional
improvement andminimize the risk of postoperative compli-
cations, we do believe that endoprosthetic reconstructions of
a nonneoplastic disease should be performed in high-volume
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centers to treat well selected patients after a careful consider-
ation of both surgical alternatives and desired outcomes.
In this work, we aimed to evaluate our experience in the
use of modular endoprostheses for the treatment of nonneo-
plastic conditions. Particularly, we sought to investigate both
complications and failures occurred in our patients.
2. Materials and Methods
2.1. Study Population. The study was approved by the local
ethical committee, and the research was performed in com-
pliance with the Helsinki Declaration. We reviewed data
from consecutive patients who have undergone a modular
endoprosthetic replacement at our institution from January
2001 to December 2014. Patients who received a megapros-
thetic implant for the treatment of a nonneoplastic or post-
neoplastic (i.e., the treatment of a failed oncologic surgery
in a recurrence-free patient) condition are included in this
retrospective study.
In the study period, 509 modular endoprostheses of the
lower limb were implanted in 509 patients. Of them, 87 were
used to manage nonneoplastic or postneoplastic conditions
of severe bone loss andwere included in the study.There were
54 (62.1%) females and 33 (37.9%)males, averaging 61 (18–93)
years at the index procedure.
Indications for the use of the megaprosthesis were the
management of fracture sequelae in 34 (39.1%) patients,
total hip arthroplasty revision in 23 (26.4%) patients (due to
aseptic loosening in 15 cases, periprosthetic joint infection in
7 cases, and instability in 1 cases), a total knee arthroplasty
revision in 14 (16.1%) patients (due to periprosthetic joint
infection in 8 cases, aseptic loosening in 5 cases, and pros-
thesis disassembly in 1 case), themanagement of sequelae of a
failed osteoarticular graft in 7 (8%) patients, themanagement
of a periprosthetic fracture in 4 (4.6%) patients, a megapros-
thesis revision in 4 (4.6%) patients, and a combined total hip
and knee arthroplasty revision (due to aseptic loosening) in 1
(1.1%) patient. Overall, in 25 (28.7%) patients’ clinical history
a previous surgical site infection has been detected. Twenty-
one (24.1%) patients underwent megaprosthetic reconstruc-
tion in postneoplastic conditions; of them, 5 patients pre-
viously underwent radiation therapy, 4 patients previously
underwent chemotherapy, and 2 patients previously under-
went a combined chemotherapy and radiation therapy.
2.2. Surgical Technique. All surgical procedures were per-
formed under general anesthesia. The Megasystem-C
(Waldemar LINK GmbH & Co. KG, Hamburg, FRG)
modular system was used in all cases. In detail, 40 (46%)
proximal femoral endoprostheses, 26 (29.9%) distal femoral
endoprostheses, 9 (10.3%) proximal tibial endoprostheses, 8
(9.2%) knee arthrodesis endoprostheses, and 4 (4.6%) total
femoral endoprostheses were implanted.
A conventional megaprosthesis was used in all but 3
patients that received a proximal tibial allograft-prosthesis
composite. Among patients complaining of a previous sur-
gical site infection, 12 of them received a silver-coated
endoprosthesis trying to minimize the risk of postopera-
tive perimegaprosthetic infection [15]. For endoprosthetic
reconstructions of the knee, reconstruction of the extensor
mechanismwas accomplished by suturing the patellar tendon
on the tibial component, which provides a fixation cage on
its proximal part. A rotating hinge mechanism was used in
all cases, and resurfacing of the patella was not performed in
any case. In proximal femoral procedures, reconstruction of
the abductor mechanism was accomplished by suturing the
vastus lateralis and gluteus medius on the prosthesis, which
provides holes on its proximal part.
The implant system we used provides either cemented or
cementless stems. Cemented fixation of the stem was used
in our series in 60% of cases. In detail, we preferred to
use cemented stems in irradiated bone, in old patients with
osteoporotic bone, andwhen the shape of themedullary canal
did not allow an adequate press-fit fixation [1].
All patients received a 6-week pharmacological subcu-
taneous thromboembolism prevention therapy with low-
molecular-weight heparin. Standard antibiotic proxylaxis
regimen consisted of a one-week pharmacological venous
administration of vancomycin-containing prophylaxis fol-
lowed by a one-week oral administration of 𝛽-lactams; this
regimen was modified in specific cases as a previous surgical
site infection, renal insufficiency, or allergy.
2.3. Patient Evaluation. A complete clinical history was
obtained from all patients. Initial and follow-up data were
extracted fromourmedical records relating to follow-up eval-
uations. Patients with insufficient data in our database were
recalled and evaluated. Specifically, patients were reviewed
for both complications and failure of their megaprosthetic
implant. Complications were classified according to the
system by Henderson et al. [16], as previously modified
for its use in nonneoplastic conditions [6], into soft-tissue
complications (type 1), aseptic loosening (type 2), structural
complications (type 3), and perimegaprosthetic infections
(type 4). Failed reconstructions were defined as those having
required complete revision of the endoprosthesis, unplanned
revision of a failed portion of the endoprosthesis, fixation of
a periprosthetic fracture, soft-tissue reconstruction to restore
joint stability, endoprosthetic removal without revision, and
amputation [16].The mean follow-up was 58 (1–167) months.
2.4. Statistical Analysis. The mean and range were reported
for the continuous variables, whereas counts and percents
described the categorical variables. Survival curves were
established with the Kaplan-Meier method [17], and the
difference in cumulative survival between groups of patients
was assessed with the Mantel-Cox log-rank test. The Cox
regression analysis was used to test the effect of possible
covariates.
The IBM SPSS Statistics 21.0.0.1 software (IBM Corp.,
Armonk, NY, USA) was used for the database construction
and the statistical analysis. 2-tailed 𝑝 < 0.05 was considered
significant.
3. Results
3.1. Soft-Tissue Complications. Eight cases (9.2%) of disloca-
tion were recorded among the 44 proximal or total femoral
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endoprostheses, occurring 12 (1–40) months after the index
procedure. In all but 1 case, a bipolar head has been used;
1 constrained cup has been furtherly used. Overall, 3 dis-
locations were recurrent. A closed reduction was effectively
performed in 4 patients, whereas 4 patients underwent an
acetabular component revision (with retentive cups having
been used in 2 cases) with or without an associated femoral
component revision.
One patient treated with a proximal tibial endoprosthesis
experienced an extensor mechanism failure 52 months post-
operatively, and an allograft reconstruction was performed.
A mobilization of the fixation cage for the patellar tendon
occurred in 2 cases 12 and 52 months after the index
procedure; as no deficit of the extensor mechanism occurred,
the cage was removed in both cases.
With failures related to soft-tissue complications consid-
ered as endpoint, endoprostheses survival was 96.5% at 1 year,
95.1% at 2 years, and 93% at 5 and 10 years.
3.2. Aseptic Loosening. Overall, aseptic loosening occurred
in 2 (2.3%) cases 23 months postoperatively. Specifically, one
patient who underwent a distal femoral replacement exhi-
bited a mobilization of the cemented femoral stem, thus
requiring a megaprosthetic revision and the implant of a
total femoral endoprosthesis. One patient experienced a
posttraumatic mobilization of the acetabular component of a
proximal femoral endoprosthesis, and a revision of the com-
ponent was performed.
With failures related to aseptic loosening considered as
endpoint, endoprostheses survival was 100% at 1 years and
97.1% at 2 at 5 and 10 years.
3.3. Structural Complications. Globally, 6 (6.9%) structural
complications were noted. Specifically, 4 periprosthetic frac-
tures of the femur (3) and tibia (1) meanly occurred 41 (23–
59) months after the index procedure. One fracture healed
with a long leg cast immobilization, one further case required
an internal fixation and bone graft implant, and a mega-
prosthetic revision was performed in the remnant 2 cases. A
megaprosthetic disassembly occurred 22 months postopera-
tively due to a fracture of one of the Morse tapers connecting
two contiguous modules: a revision of the involved modules
was then performed. A fracture of both the ceramic compo-
nent andpolyethylene insert of a proximal femoralmegapros-
thesis occurred 24 months postoperatively: a megaprosthetic
revision was then performed.
With failures related to structural complications consid-
ered as endpoint, endoprostheses survival was 100% at 1 year,
95.6% at 2 years, and 90.4% at 5 and 10 years.
3.4. Perimegaprosthetic Infections. Overall, infection oc-
curred in 10 (11.5%) patients (in detail, 5 proximal femoral
endoprostheses, 3 distal femoral endoprostheses, 1 proximal
tibial endoprosthesis, and 1 total femoral endoprosthesis)
23 (1–63) months after the index procedure. Of them, 3
patients had history of a previous surgical site infection,
3 patients received a silver-coated endoprosthesis, and 2
patients previously underwent radiation therapy. In all but
one case a megaprosthetic revision was performed: in detail,
one patient received a suppressive antibiotic therapy on the
basis of his medical status and contraindication to surgery,
and he died from comorbidities being the infection still
persistent. Of the 9 performed surgeries, there were 6 two-
stage revisions (in one case the second stage was not per-
formed due to the patient’s death) and 3 one-stage revisions.
Finally, infection still persisted in 2 patients that underwent
a two-stage revision, and a hip disarticulation was then per-
formed.
With failures related to perimegaprosthetic infections
considered as endpoint, endoprostheses survival was 95.1%
at 1 year, 90.7% at 2 years, 89% at 5 years, and 86.3% at 10
years. There was no significant difference in the survival rate
according to the reconstruction site (𝑝 = 0.987), nor to the
history of a previous surgical site infection (𝑝 = 0.238).
3.5. Overall Survival Analysis. With any implant failure con-
sidered as endpoint, whichever first occurred, overall endo-
prostheses survival was 91.5% at 1 year, 80% at 2 years, 71.6% at
5 years, and 69.1% at 5 and 10 years. There was no significant
difference in the survival rate according to the diagnosis at
the index procedure (𝑝 = 0.921), nor to the reconstruction
site (𝑝 = 0.402).
The use of megaprostheses in a postneoplastic setting did
not affect survival rate in comparison with endoprosthetic
reconstruction of nonneoplastic conditions (𝑝 = 0.851).
4. Discussion
The development of megaprostheses for large resections has
provided important options to orthopaedic oncologist sur-
geons for the replacement of skeletal segments.Megaprosthe-
ses are currently gaining momentum, at least in high-volume
centers, as a useful and effective reconstructive strategy for
severe bone loss following nonneoplastic conditions, such as
a failed joint replacement or fracture, complex periprosthetic
fractures, and severe instabilities of distal femoral prostheses.
Though promising results have been published [2–14], the use
of megaprostheses in such cases should be considered as a
limb salvage option in carefully selected patients, when other
surgical options are unfeasible [6].
Implant survival is still the main concern that may limit
the routine use of endoprostheses to manage nonneoplastic
conditions. We found an overall failure-free survival was
91.5% at 1 year, 80% at 2 years, 71.6% at 5 years, and 69.1% at
5 and 10 years, without significant difference in the survival
rate according to the diagnosis at the index procedure nor
to the reconstruction site (Table 1). Our results slightly differ
from those of the previously published literature: Berend
and Lombardi [18] found encouraging results with an overall
reoperation-free survival of 97% at 1 year, 95% at 2 years,
and 83% at 5 years after distal femoral replacement. On
the contrary the systematic reviews by Korim et al. [6, 7]
pointed out a mean failure rate of 76% at 3.8 years for
proximal femoral prostheses [6] and 83% at 3.3 years for distal
femoral prostheses [7]. We may explain such discrepancies
by assuming that our survival analysis was carried out con-
sidering failures according to Henderson et al. [16] rather
than overall reoperations as endpoints.
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Table 1: Overview of complications according to the surgical site.
Proximal endoprostheses: PF and
TF endoprostheses, 𝑛 = 44
Distal endoprostheses: DF, KA,
and PT endoprostheses, 𝑛 = 43
Type 1: soft-tissue complications, 𝑛 = 11 8 3
Type 2: aseptic loosening, 𝑛 = 2 1 1
Type 3: structural complications, 𝑛 = 6 4 2
Type 4: perimegaprosthetic infections, 𝑛 = 10 6 4
PF: proximal femoral.
TF: total femoral.
DF: distal femoral.
KA: knee arthrodesis.
PT: proximal tibia.
Periprosthetic joint infection remains one of the most
challenging complications following joint replacement and
a leading cause of early implant failure [19]. Whilst overall
infection rate is relatively low, being approximately 1% fol-
lowing hip and knee arthroplasties [20], it might dramatically
increase in the presence of certain risk factors, as in the case
of patients’ poor health status, extensive soft-tissue dissec-
tion, long operating times, and the need of multiple blood
transfusions [21–23]. In this light, a deep infection may be a
devastating complication following megaprosthetic replace-
ment, posing a high risk for repeated surgical procedures,
poor functional outcome, and failed limb salvage. Overall, a
recent systematic review [24] has reported amean rate of per-
imegaprosthetic infection of 10% following tumor resection.
In the current series, an infection rate of 11.5% in nonneoplas-
tic conditions has been observed, thus being in agreement
with previous findings of a mean rate of 7.6% for proximal
femoral prostheses [6] and 15% for distal femoral prostheses
[7].
Several risk factors for perimegaprosthetic infections
have been previously identified. Among them, a medical
history complaining of a previous surgical site infection has
been previously advocated as a leading risk factor for reinfec-
tion after tumor resection and endoprosthetic reconstruction
[25, 26]. Data of the current study contrasts with those of the
previous published literature, as we detected that the history
of a previous surgical site infection did not affect survival rate.
We may explain this discrepancy by assuming that the use of
silver-coated megaprostheses in such critical patients might
have minimized the risk of perimegaprosthetic infection
[15].
We detected 8 cases of dislocation, being the 18% of
proximal and total femoral endoprostheses of our series; a
revision procedure was performed in 4 (4.6%) patients. Our
results are in agreement with those of the systematic review
by Korim et al. [6], reporting a rate of 15.7% at a mean
follow-up of 45 months, thus dislocation being most com-
mon complication of proximal femoral prostheses for non-
neoplastic conditions. Of interest, a higher midterm rate of
37.5% has been previously reported when using proximal
femoral endoprostheses as revision arthroplasties [13]. Con-
versely, dislocation rate ofmodular endoprostheses for tumor
reconstruction is globally lower. In their retrospective review
of 2174 patients, Henderson et al. [16] detected an overall
rate of soft-tissue complications (i.e., including dislocation)
of 5.2% in primary proximal femoral prostheses. Moreover,
we previously detected a dislocation rate of 4.3% in proximal
femoral resections of 200 patients [1]. While conjectural, we
may assume that such a discrepancy between dislocation
rates is related to the systematic acetabular replacement in
nonneoplastic conditions, whereas tumor resection often
benefits from a cephalic megaprosthesis.
Both structural failures and aseptic loosening represent
minor complications in the current series, with low rates
being consistent with those we previously detected after
tumor resection [1]. Of interest, aseptic loosening of mega-
prostheses in the treatment of nonneoplastic diseases has
been previously detected with rates ranging from 0% to 9.5%
[2, 3, 8–10, 13].
Main limitations of this study include the small sample
size and lack of a control group with a different endopros-
thetic reconstruction system.The average length of follow-up
(i.e., 58 months) is still inadequate to draw definite conclu-
sions on the implant longevity and survivorship, posing a cer-
tain risk to underestimate the actual failure rate. As a further
limitation, we did not perform a postoperative evaluation of
functionality and quality of life of the patients [18, 27]. Limits
and potential biases arising from the retrospective design
should be finally considered.
5. Conclusions
Our results support the use of modular endoprostheses
as a solution to manage complex nonneoplastic diseases.
Though perimegaprothetic infection still remains the leading
complication, an overall survival rate of 69.1% at 10 years,
without significant difference in the survival rate according to
the diagnosis at the index procedure nor to the reconstruction
site, represents a promising result in such a complex surgical
procedure. Indeed, in cases of severe bone loss associated
with a failed joint replacement or fracture, a megaprosthetic
reconstruction may be the sole effective procedure that can
be performed.
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